Full Breakdown
Innovative Immunotherapy Trial Offers Hope for Colorectal Cancer Patients
3/15/2026, 8:33:15 AM
Patient Background and Diagnosis
Spencer Laird, a 30-year-old mechanic from South Carolina, was diagnosed with colorectal cancer at the age of 25 after initially being misdiagnosed with hemorrhoids. Following surgery that removed 16 inches of his colon, Laird believed he had overcome the disease. However, during a routine follow-up in December 2024, his wife, CarleyAnn Laird, insisted on a full-body scan, which revealed the cancer had returned and metastasized to his lungs, with 13 tumors present. His prognosis was grim, with doctors estimating he had about two years to live.
Exploring Treatment Options
Faced with a terminal diagnosis, Laird and his wife sought alternative treatments. CarleyAnn applied for several clinical trials, including one at Duke University led by Dr. Nicholas DeVito, focusing on the use of immunotherapy for microsatellite stable colorectal cancer. Traditionally, immunotherapy is administered after chemotherapy has failed, but DeVito's trial aimed to evaluate its effectiveness as a first-line treatment.
Trial Participation and Results
In February 2025, Laird became one of 15 participants in the trial, receiving immunotherapy infusions every two weeks. Initial scans indicated a remarkable response, with Laird's tumors shrinking significantly—from 13 tumors to just three, the largest now measuring only 0.6 millimeters. Laird described the experience as "a miracle from God," expressing disbelief at the transformation of his condition.
Implications for Future Treatments
Dr. DeVito noted that Laird's strong response to the treatment could pave the way for future research into immunotherapy as a standard care option for microsatellite stable colorectal cancer. While the full results of the trial are expected to be published in April, the preliminary findings suggest that immunotherapy may provide a viable alternative for patients who wish to avoid chemotherapy.
Expert Perspectives
Experts like Dr. Michael James Overman from the University of Texas MD Anderson Cancer Center emphasize that while the trial is groundbreaking, more research is needed to determine which patient populations might benefit most from early immunotherapy. Overman stated, "This here is proof of concept. You can do it front line, and there's definitely some activity," highlighting the potential for immunotherapy to change treatment paradigms.
Ongoing Journey and Support
Although Laird is not cancer-free, his disease is no longer considered terminal. He continues to receive treatment at Duke every two weeks and has found support from family and his church community. Reflecting on his journey, Laird remarked, "It really just taught me to try to live life. If the good Lord wakes you up every day and you got breath in your lungs, just go do something."
Conclusion
The Laird family's experience underscores the potential of innovative treatments like immunotherapy in the fight against colorectal cancer. As research progresses, it may offer new hope for patients facing similar diagnoses.
